| CHD |
Report |
Organic sales growth |
BEAT |
pred ~3.4% vs. cons 3.0% |
MEDIUM |
| CHD |
Report |
Adjusted gross-margin expansion |
BEAT |
pred ~60 bps vs. cons 50 bps |
MEDIUM |
| CHD |
Report |
Adjusted EPS |
BEAT |
pred ~$0.89 vs. cons $0.88 |
MEDIUM |
| CHD |
Guide |
FY26 organic sales growth |
UNCHANGED |
guide ~3.5% vs. cons 3.5% (FY26) |
HIGH |
| CHD |
Guide |
FY26 adjusted EPS |
UNCHANGED |
guide ~$3.76 vs. cons $3.76 (FY26) |
MEDIUM |
| CHD |
Guide |
FY26 adjusted gross-margin expansion |
UNCHANGED |
guide ~100 bps vs. cons 100 bps (FY26) |
MEDIUM |
| CHD |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.5% |
— |
MEDIUM |
| CHD |
Return |
5-day cumulative residual |
+1.0% (STABILIZE) |
A modest ~3.4% organic-sales result and ~$0.89 EPS support a positive initial reaction, but an unchanged FY26 EPS midpoint of ~$3.76 versus consensus ~$3.76 leaves limited out-period estimate upside; revisions should remain broadly flat after the beat. |
MEDIUM |